Sacituzumab Tirumotecan Plus Pembrolizumab Meets Phase III Endpoint in First-Line PD-L1-Negative Non-Squamous NSCLC›

OncoDailySacituzumab Tirumotecan Plus Pembrolizumab Meets Phase III Endpoint in First-Line PD-L1-Negative Non-Squamous NSCLC

10h ago

0

Manila TimesKelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint

2d ago· By PR Newswire

0